Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

265 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer.
Henry NL, Skaar TC, Dantzer J, Li L, Kidwell K, Gersch C, Nguyen AT, Rae JM, Desta Z, Oesterreich S, Philips S, Carpenter JS, Storniolo AM, Stearns V, Hayes DF, Flockhart DA. Henry NL, et al. Among authors: oesterreich s. Breast Cancer Res Treat. 2013 Apr;138(3):807-16. doi: 10.1007/s10549-013-2504-3. Epub 2013 Apr 2. Breast Cancer Res Treat. 2013. PMID: 23546553 Free PMC article. Clinical Trial.
Low SAFB levels are associated with worse outcome in breast cancer patients.
Hammerich-Hille S, Bardout VJ, Hilsenbeck SG, Osborne CK, Oesterreich S. Hammerich-Hille S, et al. Among authors: oesterreich s. Breast Cancer Res Treat. 2010 Jun;121(2):503-9. doi: 10.1007/s10549-008-0297-6. Epub 2009 Jan 10. Breast Cancer Res Treat. 2010. PMID: 19137425
Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients.
Rae JM, Sikora MJ, Henry NL, Li L, Kim S, Oesterreich S, Skaar TC, Nguyen AT, Desta Z, Storniolo AM, Flockhart DA, Hayes DF, Stearns V; COBRA investigators. Rae JM, et al. Among authors: oesterreich s. Pharmacogenomics J. 2009 Aug;9(4):258-64. doi: 10.1038/tpj.2009.14. Epub 2009 May 5. Pharmacogenomics J. 2009. PMID: 19421167 Free PMC article. Clinical Trial.
Nuclear receptor coregulator SNP discovery and impact on breast cancer risk.
Hartmaier RJ, Tchatchou S, Richter AS, Wang J, McGuire SE, Skaar TC, Rae JM, Hemminki K, Sutter C, Ditsch N, Bugert P, Weber BH, Niederacher D, Arnold N, Varon-Mateeva R, Wappenschmidt B, Schmutzler RK, Meindl A, Bartram CR, Burwinkel B, Oesterreich S. Hartmaier RJ, et al. Among authors: oesterreich s. BMC Cancer. 2009 Dec 14;9:438. doi: 10.1186/1471-2407-9-438. BMC Cancer. 2009. PMID: 20003447 Free PMC article.
The p160 ER co-regulators predict outcome in ER negative breast cancer.
Spears M, Oesterreich S, Migliaccio I, Guiterrez C, Hilsenbeck S, Quintayo MA, Pedraza J, Munro AF, Thomas JS, Kerr GR, Jack WJ, Kunkler IH, Cameron DA, Chetty U, Bartlett JM. Spears M, et al. Among authors: oesterreich s. Breast Cancer Res Treat. 2012 Jan;131(2):463-72. doi: 10.1007/s10549-011-1426-1. Epub 2011 Mar 9. Breast Cancer Res Treat. 2012. PMID: 21390497
Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth.
Casa AJ, Potter AS, Malik S, Lazard Z, Kuiatse I, Kim HT, Tsimelzon A, Creighton CJ, Hilsenbeck SG, Brown PH, Oesterreich S, Lee AV. Casa AJ, et al. Among authors: oesterreich s. Breast Cancer Res Treat. 2012 Feb;132(1):61-73. doi: 10.1007/s10549-011-1540-0. Epub 2011 May 4. Breast Cancer Res Treat. 2012. PMID: 21541704 Free PMC article.
A SNP in steroid receptor coactivator-1 disrupts a GSK3β phosphorylation site and is associated with altered tamoxifen response in bone.
Hartmaier RJ, Richter AS, Gillihan RM, Sallit JZ, McGuire SE, Wang J, Lee AV, Osborne CK, O'Malley BW, Brown PH, Xu J, Skaar TC, Philips S, Rae JM, Azzouz F, Li L, Hayden J, Henry NL, Nguyen AT, Stearns V, Hayes DF, Flockhart DA, Oesterreich S. Hartmaier RJ, et al. Among authors: oesterreich s. Mol Endocrinol. 2012 Feb;26(2):220-7. doi: 10.1210/me.2011-1032. Epub 2011 Dec 15. Mol Endocrinol. 2012. PMID: 22174377 Free PMC article.
265 results